ATE419245T1 - Cinnoline verbindungen - Google Patents

Cinnoline verbindungen

Info

Publication number: ATE419245T1
Authority: AT; Austria
Prior art keywords: sub; sup; alkyl; represents hydrogen; formula
Prior art date: 2000-08-09

Application number

AT01954175T

Other languages

English (en)

Inventor

Laurent Francois Andre Hennequin

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-08-09

Filing date

2001-08-07

Publication date

2009-01-15

2001-08-07 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2009-01-15 Application granted granted Critical

2009-01-15 Publication of ATE419245T1 publication Critical patent/ATE419245T1/de

Links

WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical class N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 title 1
125000000217 alkyl group Chemical group 0.000 abstract 8
150000001875 compounds Chemical class 0.000 abstract 5
229910052739 hydrogen Inorganic materials 0.000 abstract 5
239000001257 hydrogen Substances 0.000 abstract 5
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 3
125000003545 alkoxy group Chemical group 0.000 abstract 3
150000003839 salts Chemical class 0.000 abstract 3
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 abstract 2
-1 N-methylpiperazinly Chemical group 0.000 abstract 2
229910052799 carbon Inorganic materials 0.000 abstract 2
125000004432 carbon atom Chemical group C* 0.000 abstract 2
125000005843 halogen group Chemical group 0.000 abstract 2
150000002431 hydrogen Chemical class 0.000 abstract 2
125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
238000004519 manufacturing process Methods 0.000 abstract 2
BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 abstract 1
241001465754 Metazoa Species 0.000 abstract 1
206010028980 Neoplasm Diseases 0.000 abstract 1
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 abstract 1
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 abstract 1
239000004480 active ingredient Substances 0.000 abstract 1
230000001772 anti-angiogenic effect Effects 0.000 abstract 1
125000002393 azetidinyl group Chemical group 0.000 abstract 1
201000011510 cancer Diseases 0.000 abstract 1
125000004093 cyano group Chemical group *C#N 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 abstract 1
PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 abstract 1
RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 abstract 1
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
229910052757 nitrogen Inorganic materials 0.000 abstract 1
125000004043 oxo group Chemical group O=* 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
125000004193 piperazinyl group Chemical group 0.000 abstract 1
125000003386 piperidinyl group Chemical group 0.000 abstract 1
125000000719 pyrrolidinyl group Chemical group 0.000 abstract 1
230000001603 reducing effect Effects 0.000 abstract 1
206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
125000005505 thiomorpholino group Chemical group 0.000 abstract 1
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
230000008728 vascular permeability Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Diabetes (AREA)
Rheumatology (AREA)
Endocrinology (AREA)
Ophthalmology & Optometry (AREA)
Vascular Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Obesity (AREA)
Cardiology (AREA)
Transplantation (AREA)
Urology & Nephrology (AREA)
Emergency Medicine (AREA)
Reproductive Health (AREA)
Pain & Pain Management (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)

AT01954175T 2000-08-09 2001-08-07 Cinnoline verbindungen ATE419245T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP00402255		2000-08-09

Publications (1)

Publication Number	Publication Date
ATE419245T1 true ATE419245T1 (de)	2009-01-15

Family

ID=8173806

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT01954175T ATE419245T1 (de)	2000-08-09	2001-08-07	Cinnoline verbindungen

Country Status (17)

Country	Link
US (1)	US6887874B2 (de)
EP (1)	EP1309587B1 (de)
JP (1)	JP2004505966A (de)
KR (1)	KR100834823B1 (de)
CN (1)	CN1252065C (de)
AT (1)	ATE419245T1 (de)
AU (2)	AU2001276521B2 (de)
BR (1)	BR0113057A (de)
CA (1)	CA2415022A1 (de)
DE (1)	DE60137234D1 (de)
ES (1)	ES2317923T3 (de)
IL (2)	IL153805A0 (de)
MX (1)	MXPA02012943A (de)
NO (1)	NO326475B1 (de)
NZ (1)	NZ523388A (de)
WO (1)	WO2002012228A1 (de)
ZA (1)	ZA200300221B (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR20080015482A (ko)	1999-02-10	2008-02-19	아스트라제네카 아베	혈관형성 억제제로서의 퀴나졸린 유도체
EP1676845B1 (de)	1999-11-05	2008-06-11	AstraZeneca AB	Neue Quinazolin-Derivate
JP2003525897A (ja)	2000-03-06	2003-09-02	アストラゼネカアクチボラグ	治療
ES2267748T3 (es) *	2000-04-07	2007-03-16	Astrazeneca Ab	Compuestos de quinazolina.
RU2365588C2 (ru)	2002-02-01	2009-08-27	Астразенека Аб	Хиназолиновые соединения
TW200400034A (en)	2002-05-20	2004-01-01	Bristol Myers Squibb Co	Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors
CA2503371C (en)	2002-11-04	2011-01-11	Astrazeneca Ab	Quinazoline derivatives as src tyrosine kinase inhibitors
US7109337B2 (en)	2002-12-20	2006-09-19	Pfizer Inc	Pyrimidine derivatives for the treatment of abnormal cell growth
PT1625121E (pt)	2002-12-20	2010-03-11	Pfizer Prod Inc	Derivados de piridina para o tratamento de crescimento celular anormal
GB0318422D0 (en) *	2003-08-06	2003-09-10	Astrazeneca Ab	Chemical compounds
BRPI0511132A (pt)	2004-05-14	2007-11-27	Pfizer Prod Inc	derivados de pirimidina e composição farmacêutica compreendendo os mesmos
MXPA06013164A (es)	2004-05-14	2007-02-13	Pfizer Prod Inc	Derivados de pirimidina para el tratamiento de crecimiento de celulas anormal.
MXPA06013165A (es)	2004-05-14	2007-02-13	Pfizer Prod Inc	Derivados de pirimidina para el tratamiento de crecimiento de celulas anormal.
MX2007002592A (es) *	2004-09-03	2007-10-10	Memory Pharm Corp	Derivados 4,6 -dialcoxi - cinnolina 4 - sustituidos como inhibidores de la fosfodiesterasa 10 para el tratamiento de sindromes psiquiatricos o neurologicos.
US7700595B2 (en) *	2005-03-01	2010-04-20	Wyeth Llc	Cinnoline compounds
AU2007217474A1 (en) *	2006-02-21	2007-08-30	Amgen Inc.	Cinnoline derivatives as phosphodiesterase 10 inhibitors
MX2008010953A (es) *	2006-02-28	2008-09-08	Amgen Inc	Derivados de cinolina y quinoxalina como inhibidores de la fosfodiesterasa 10.
US20080190689A1 (en) *	2007-02-12	2008-08-14	Ballard Ebbin C	Inserts for engine exhaust systems
US8921533B2 (en)	2011-07-25	2014-12-30	Chromatin Technologies	Glycosylated valproic acid analogs and uses thereof
US9353150B2 (en)	2012-12-04	2016-05-31	Massachusetts Institute Of Technology	Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
US10201623B2 (en)	2013-03-15	2019-02-12	Memorial Sloan Kettering Cancer Center	HSP90-targeted cardiac imaging and therapy
CN104370825B (zh) *	2014-09-29	2017-04-19	人福医药集团股份公司	作为激酶抑制剂的取代杂环化合物及其制备方法和用途
US10918627B2 (en)	2016-05-11	2021-02-16	Massachusetts Institute Of Technology	Convergent and enantioselective total synthesis of Communesin analogs
WO2018064465A1 (en)	2016-09-29	2018-04-05	The Regents Of The University Of California	Compounds for increasing neural plasticity
US11932650B2 (en)	2017-05-11	2024-03-19	Massachusetts Institute Of Technology	Potent agelastatin derivatives as modulators for cancer invasion and metastasis
US10640508B2 (en)	2017-10-13	2020-05-05	Massachusetts Institute Of Technology	Diazene directed modular synthesis of compounds with quaternary carbon centers
WO2020176599A1 (en)	2019-02-27	2020-09-03	The Regents Of The University Of California	Azepino-indoles and other heterocycles for treating brain disorders
US11535634B2 (en)	2019-06-05	2022-12-27	Massachusetts Institute Of Technology	Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
US12030888B2 (en)	2021-02-24	2024-07-09	Massachusetts Institute Of Technology	Himastatin derivatives, and processes of preparation thereof, and uses thereof
WO2023114313A1 (en)	2021-12-15	2023-06-22	Delix Therapeutics, Inc.	Phenoxy and benzyloxy substituted psychoplastogens and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL81307A0 (en)	1986-01-23	1987-08-31	Union Carbide Agricult	Method for reducing moisture loss from plants and increasing crop yield utilizing nitrogen containing heterocyclic compounds and some novel polysubstituted pyridine derivatives
IL89029A (en)	1988-01-29	1993-01-31	Lilly Co Eli	Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them
US5480883A (en)	1991-05-10	1996-01-02	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
DK0584222T3 (da)	1991-05-10	1998-02-23	Rhone Poulenc Rorer Int	Bis-mono- og bicycliske aryl- og heteroarylforbindelser, som inhiberer EGF- og/eller PDGF-receptor-tyrosinkinase
AU680870B2 (en) *	1993-04-28	1997-08-14	Astellas Pharma Inc.	New heterocyclic compounds
ATE300521T1 (de) *	1996-09-25	2005-08-15	Astrazeneca Ab	Chinolin-derivate die den effekt von wachstumsfaktoren wie vegf vezögern
JP4073961B2 (ja)	1996-10-01	2008-04-09	協和醗酵工業株式会社	含窒素複素環化合物
JP2002501532A (ja)	1997-05-30	2002-01-15	メルクエンドカンパニーインコーポレーテッド	新規血管形成阻害薬
US6162804A (en)	1997-09-26	2000-12-19	Merck & Co., Inc.	Tyrosine kinase inhibitors
GB9721437D0 (en)	1997-10-10	1997-12-10	Glaxo Group Ltd	Heteroaromatic compounds and their use in medicine
PE20010306A1 (es)	1999-07-02	2001-03-29	Agouron Pharma	Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa

2001
- 2001-08-07 AT AT01954175T patent/ATE419245T1/de not_active IP Right Cessation
- 2001-08-07 US US10/333,592 patent/US6887874B2/en not_active Expired - Fee Related
- 2001-08-07 CN CNB018139167A patent/CN1252065C/zh not_active Expired - Fee Related
- 2001-08-07 BR BR0113057-9A patent/BR0113057A/pt not_active IP Right Cessation
- 2001-08-07 DE DE60137234T patent/DE60137234D1/de not_active Expired - Fee Related
- 2001-08-07 AU AU2001276521A patent/AU2001276521B2/en not_active Ceased
- 2001-08-07 IL IL15380501A patent/IL153805A0/xx unknown
- 2001-08-07 MX MXPA02012943A patent/MXPA02012943A/es active IP Right Grant
- 2001-08-07 AU AU7652101A patent/AU7652101A/xx active Pending
- 2001-08-07 JP JP2002518203A patent/JP2004505966A/ja active Pending
- 2001-08-07 ES ES01954175T patent/ES2317923T3/es not_active Expired - Lifetime
- 2001-08-07 WO PCT/GB2001/003533 patent/WO2002012228A1/en not_active Ceased
- 2001-08-07 NZ NZ523388A patent/NZ523388A/en unknown
- 2001-08-07 EP EP01954175A patent/EP1309587B1/de not_active Expired - Lifetime
- 2001-08-07 CA CA002415022A patent/CA2415022A1/en not_active Abandoned
- 2001-08-07 KR KR1020037001922A patent/KR100834823B1/ko not_active Expired - Fee Related
2003
- 2003-01-05 IL IL153805A patent/IL153805A/en not_active IP Right Cessation
- 2003-01-08 ZA ZA200300221A patent/ZA200300221B/en unknown
- 2003-02-07 NO NO20030624A patent/NO326475B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
NO20030624L (no)	2003-04-07
MXPA02012943A (es)	2003-05-15
US20030212055A1 (en)	2003-11-13
AU7652101A (en)	2002-02-18
JP2004505966A (ja)	2004-02-26
BR0113057A (pt)	2003-07-08
NZ523388A (en)	2004-09-24
IL153805A (en)	2009-05-04
ES2317923T3 (es)	2009-05-01
EP1309587A1 (de)	2003-05-14
ZA200300221B (en)	2004-04-08
CA2415022A1 (en)	2002-02-14
US6887874B2 (en)	2005-05-03
IL153805A0 (en)	2003-07-31
KR100834823B1 (ko)	2008-06-09
WO2002012228A1 (en)	2002-02-14
NO326475B1 (no)	2008-12-08
KR20030022379A (ko)	2003-03-15
AU2001276521B2 (en)	2006-05-25
CN1446214A (zh)	2003-10-01
NO20030624D0 (no)	2003-02-07
EP1309587B1 (de)	2008-12-31
DE60137234D1 (de)	2009-02-12
CN1252065C (zh)	2006-04-19

Legal Events

Date	Code	Title	Description
2009-06-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE60137234D1 (de)	2009-02-12	Cinnoline verbindungen
RU2403258C2 (ru)	2010-11-10	Тиазолилдигидроиндазолы
NO991423D0 (no)	1999-03-24	Qinolinderivater som inhiberer effekten av vekstfaktorer som VEGF
RU2350605C2 (ru)	2009-03-27	Аналоги хиназолина в качестве ингибиторов рецепторных тирозинкиназ
MXPA03000252A (es)	2003-06-06	Derivados de quinolina que tienen actividad de inhibicion de fcev.
DE60320012D1 (de)	2008-05-08	Aminoheterocyclen als vr-1 antagonisten zur behandlung von schmerzen
CA2344290A1 (en)	2000-04-20	Quinazoline derivatives
ATE203524T1 (de)	2001-08-15	Chinazolin-derivate
MXPA01004256A (es)	2003-06-06	N-arilamidas del acido antranilico y del acido tioantranilico.
ATE286501T1 (de)	2005-01-15	Pyrimidinderivate
TW200517109A (en)	2005-06-01	Substituted pyridinones
NO20023934D0 (no)	2002-08-19	Nye forbindelser
MXPA03011638A (es)	2004-04-02	Nuevos derivados de 4-piperazinil indol con afinidad por el receptor 5-ht6.
IS2114B (is)	2006-06-15	Kínasólínafleiður til að meðhöndla æxli
HUP0401009A2 (hu)	2004-08-30	5-Hidroxitriptamin-6-ligandumokként alkalmazható 1-aril- vagy 1- alkil-szulfonilbenzazol-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
BR0113078A (pt)	2003-07-01	Uso de um composto, composto, processo para a preparação do mesmo, composição farmacêutica, e, método para produzir um efeito antiangiogênico e/ou redutor da permeabilidade vascular em um animal de sangue quente
HUP0103063A2 (hu)	2003-02-28	Új 2H-piridazin-származékok, alkalmazásuk, ilyen hatóanyagot tartalmazó gyógyászati készítmények, és eljárás a hatóanyag előállítására
JP2004517843A5 (de)	2005-12-22
ATE401080T1 (de)	2008-08-15	(3-((chinazolin-4-yl)amino)-1h-pyrazol-1- yl)acetamid derivate und verwandte verbindungen als aurora kinase inhibitoren zur behandlung von proliferativen erkrankungen wie krebs
AR035465A1 (es)	2004-05-26	Compuestos de imidazopiridina, procesos para su preparacion,formulacion farmaceutica, usos de estos compuestos para la fabricacion de medicamentos e intermediarios
MY137835A (en)	2009-03-31	Quinazoline derivatives as src tyrosine kinase inhibitors
MY140653A (en)	2010-01-15	Substituted diketopiperazines and their use as oxytocyn antagonists
UA74341C2 (uk)	2005-12-15	Похідні борелідину, які інгібують ангіогенез
EA200100725A2 (ru)	2002-02-28	Новые бензотиадиазиновые соединения, способ их получения и их содержащие фармацевтические композиции
SE0301371D0 (sv)	2003-05-09	New Compounds